180 Wealth Advisors LLC Increases Stock Position in abrdn Life Sciences Investors $HQL

180 Wealth Advisors LLC increased its position in shares of abrdn Life Sciences Investors (NYSE:HQL) by 5.1% during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 143,098 shares of the company’s stock after purchasing an additional 6,976 shares during the quarter. 180 Wealth Advisors LLC owned approximately 0.50% of abrdn Life Sciences Investors worth $1,833,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. Cambridge Investment Research Advisors Inc. purchased a new position in shares of abrdn Life Sciences Investors in the 1st quarter worth approximately $134,000. Oppenheimer & Co. Inc. lifted its holdings in abrdn Life Sciences Investors by 46.5% during the first quarter. Oppenheimer & Co. Inc. now owns 28,713 shares of the company’s stock worth $364,000 after acquiring an additional 9,115 shares during the period. Allspring Global Investments Holdings LLC boosted its position in abrdn Life Sciences Investors by 16.5% in the first quarter. Allspring Global Investments Holdings LLC now owns 193,484 shares of the company’s stock worth $2,455,000 after purchasing an additional 27,433 shares during the last quarter. Stratos Wealth Partners LTD. increased its position in shares of abrdn Life Sciences Investors by 7.4% during the 1st quarter. Stratos Wealth Partners LTD. now owns 14,176 shares of the company’s stock valued at $180,000 after purchasing an additional 971 shares during the last quarter. Finally, Stephens Inc. AR increased its position in shares of abrdn Life Sciences Investors by 56.1% during the 1st quarter. Stephens Inc. AR now owns 19,336 shares of the company’s stock valued at $245,000 after purchasing an additional 6,947 shares during the last quarter. 32.21% of the stock is owned by institutional investors.

abrdn Life Sciences Investors Price Performance

Shares of NYSE:HQL opened at $16.37 on Friday. abrdn Life Sciences Investors has a fifty-two week low of $10.55 and a fifty-two week high of $16.92. The company’s 50-day moving average is $14.84 and its 200 day moving average is $13.39.

abrdn Life Sciences Investors Cuts Dividend

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, September 30th. Investors of record on Friday, August 22nd were issued a $0.42 dividend. The ex-dividend date of this dividend was Friday, August 22nd. This represents a $1.68 annualized dividend and a yield of 10.3%.

Insider Transactions at abrdn Life Sciences Investors

In other abrdn Life Sciences Investors news, major shareholder Saba Capital Management, L.P. sold 41,623 shares of the company’s stock in a transaction dated Monday, September 22nd. The shares were sold at an average price of $14.14, for a total transaction of $588,549.22. Following the sale, the insider directly owned 2,837,633 shares of the company’s stock, valued at $40,124,130.62. This represents a 1.45% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In the last quarter, insiders sold 179,906 shares of company stock valued at $2,530,720. Insiders own 10.06% of the company’s stock.

abrdn Life Sciences Investors Company Profile

Abrdn Life Sciences Investors is a closed-ended equity mutual fund launched and managed by abrdn Inc The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, devices and supplies industries, and in agriculture and environmental management industries.